α-Synuclein Aggregation in Treatment of Parkinson's Disease
Por um escritor misterioso
Descrição
Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.
Therapeutic functions of astrocytes to treat α-synuclein pathology in Parkinson's disease
ISIS Studying the influence of salts on α-synuclein aggregation, a hallmark of Parkinson's disease
Frontiers The Role of Lipids in the Initiation of α-Synuclein Misfolding
IJMS, Free Full-Text
Alpha-Synuclein aggregation HTRF kit
Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration, Acta Neuropathologica Communications
α-Synuclein Aggregation in Treatment of Parkinson's Disease
Cellular models of alpha‐synuclein toxicity and aggregation - Delenclos - 2019 - Journal of Neurochemistry - Wiley Online Library
Models of α-synuclein aggregation in Parkinson's disease, Acta Neuropathologica Communications
Digesting recent findings: gut alpha-synuclein, microbiome changes in Parkinson's disease: Trends in Endocrinology & Metabolism
de
por adulto (o preço varia de acordo com o tamanho do grupo)
